Attomarker, a pioneering diagnostics company based in the UK, has officially initiated an Acceleration Round to propel its commercial and clinical development efforts. This strategic move marks a significant step forward for the company as it seeks to expand its innovative immunology diagnostics platform.
Advancements in Immune Diagnostics
Specializing in multiplex immune diagnostics, Attomarker delivers clinically relevant immune profiling using a single, small blood sample, with results available in mere minutes. This efficiency positions the company to meet urgent clinical needs, reflected in the current adoption of its tests by healthcare professionals.
The company’s primary focus is on immune profiling for patients grappling with Long Covid, a condition that impacts over 65 million individuals globally. Attomarker’s COVID Antibody Spectrum Test categorizes patients into one of three distinct endotypes. This classification not only aids in determining suitable treatment plans but also supports ongoing disease recovery monitoring. Furthermore, Attomarker is developing two additional companion tests specifically targeting Long Covid.
Strategic Collaborations for Broader Impact
In a bid to diversify its diagnostic capabilities, Attomarker recently entered a co-development agreement with EpitogenX. This collaboration aims to integrate next-generation antigen technology into Attomarker’s existing platform, thereby enhancing immune profiling for a wider array of immune-mediated conditions that currently lack robust diagnostic solutions. Initial areas of focus include Lyme disease and Hashimoto’s disease, both of which represent significant gaps in current diagnostic offerings.
Strong Intellectual Property Foundation
Attomarker’s innovative approach is bolstered by a robust intellectual property portfolio. The company holds eight granted patents, with an additional patent pending, safeguarding its core diagnostics technology and system architecture. This strong IP position not only underpins Attomarker’s commercial strategy but also enhances its credibility in the competitive diagnostics landscape.
Current and Future Diagnostic Technologies
The diagnostics developed by Attomarker operate on a CE-marked benchtop device, which is already in clinical use. In addition, the company is actively working on a handheld device, providing a versatile option for healthcare settings that may require more portable solutions. This dual approach ensures that Attomarker can cater to diverse clinical environments, further extending its reach.
Goals of the Acceleration Round
The Acceleration Round aims to secure funding that will facilitate the commercial rollout of Attomarker’s diagnostics, support regulatory advancements, and further clinical validation. Additionally, it will contribute to the expansion of the immune profiling portfolio focused on Long Covid. Engaging retail investors through Crowdcube, a platform regulated by the UK Financial Conduct Authority, the company seeks to democratize investment opportunities while enhancing its growth trajectory.
Conclusion
Attomarker’s strategic initiatives position it at the forefront of immunology diagnostics, particularly in addressing the complexities of Long Covid. By leveraging its innovative technologies and forming key partnerships, Attomarker aims to redefine immune profiling and improve clinical outcomes for patients globally. As the company embarks on this next phase of growth, the potential for transformative advancements in diagnostics remains significant.
- Attomarker is focused on immune profiling for Long Covid, impacting over 65 million people.
- The company has developed a COVID Antibody Spectrum Test that classifies patients into three endotypes.
- A strategic partnership with EpitogenX aims to broaden diagnostic capabilities into conditions like Lyme disease.
- Attomarker holds a strong intellectual property position with eight patents granted.
- The Acceleration Round will support regulatory progress and clinical validation efforts.
Read more → www.tennessean.com